z-logo
open-access-imgOpen Access
In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity
Author(s) -
Giancarlo Renzi,
Giulia De Marco,
Michela De Meo,
Eleonora Del Rosso,
Paola Gazzaniga,
Chiara Nicolazzo
Publication year - 2022
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.121
Subject(s) - circulating tumor cell , context (archaeology) , clinical practice , cancer , in vitro , tumor cells , disease , drug , computational biology , medicine , biology , cancer research , bioinformatics , metastasis , pathology , pharmacology , genetics , paleontology , family medicine
Since taking part as leading actors in driving the metastatic process, circulating tumor cells (CTCs) have displayed a wide range of potential applications in the cancer-related research field. Besides their well-proved prognostic value, the role of CTCs in both predictive and diagnostics terms might be extremely informative about cancer properties and therefore highly helpful in the clinical decision-making process. Unfortunately, CTCs are scarcely released in the blood circulation and their counts vary a lot among different types of cancer, therefore CTC detection and consequent characterization are still highly challenging. In this context, in vitro CTC cultures could potentially offer a great opportunity to expand the number of tumor cells isolated at different stages of the disease and thus simplify the analysis of their biological and molecular features, allowing a deeper comprehension of the nature of neoplastic diseases. The aim of this review is to highlight the main attempts to establish in vitro CTC cultures from patients harboring different tumor types in order to highlight how powerful this practice could be, especially in optimizing the therapeutic strategies available in clinical practice and potentially preventing or contrasting the development of treatment resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here